[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"crohn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:crohn":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100606237","research-and-follow-up-of-the-determinants-of-the-progression-and-complications-of-inflammatory-bowel-diseases-treated-or-not-with-immunosuppressants-100606237",false,"NCT07172945","Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants.","Research and Follow-up of the Determinants of the Progression and Complications of Inflammatory Bowel Diseases Treated or Not With Immunosuppressants","SUIVITHEQUE2","Inclusion Criteria:\n\nFor all patients and control subjects\n\n* Person able to give free and informed consent.\n* Age ≥ 18 years.\n* Beneficiary of a social protection scheme or entitled person (excluding AME).\n* Consultation in the Gastroenterology and Nutrition Department of Saint-Antoine Hospital\n\nPatients with IBD :\n\n\\- Patients with Crohn's disease or haemorrhagic rectocolitis with a diagnosis established or confirmed in the Gastroenterology and Nutrition Department at Saint-Antoine Hospital.\n\nMicrobiota control' subjects:\n\n\\- Healthy subjects seen in consultation as a preventive measure or as part of stool donations for FMT.\n\nEndoscopy control' subjects:\n\n\\- Subjects with a medical indication for digestive endoscopy with biopsies:\n\n* For upper endoscopy: moderate upper digestive symptoms such as epigastralgia or pyrosis\n* For colonoscopy: moderate digestive symptoms suggestive of irritable bowel syndrome or screening for colorectal cancer.\n\nExclusion Criteria:\n\nFor all patients and control subjects\n\n* Subjects under guardianship, curatorship or safeguard of justice.\n* Subjects who do not speak French.\n\nIBD patients:\n\n\\- Colon preparation within 6 weeks before stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards).\n\nEndoscopy control' and \"microbiota control\" subjects:\n\n* Subject suffering from a chronic disease\n* Antibiotics taken in the 6 weeks prior to endoscopy\n* Antibiotics or colonic preparation taken within 6 weeks prior to stool sampling (stool samples may be taken either before colonoscopy or at least 6 weeks afterwards).",true,"ALL","18 Years",{"count":21,"type":22},4500,"ESTIMATED","INTERVENTIONAL",[25],"NA","Inflammatory Bowel Diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic, disabling conditions affecting young adults, marked by flare-ups and remissions. Traditionally, IBD was treated with immunosuppressants like thiopurines, but new biological treatments, such as anti-TNFa antibodies (e.g., infliximab, adalimumab), have transformed management. Biologics often combine with thiopurines but come with risks, like increased chances of skin cancers and lymphomas, especially for prolonged use in young patients. Recently, newer biologics (e.g., ustekinumab, vedolizumab) and small molecules like JAK inhibitors have expanded treatment options.\n\nThe exact cause of IBD remains unknown, though an inappropriate immune response to the intestinal microbiota in genetically predisposed individuals is suspected. Dysbiosis, or imbalance in gut microbiota, has been linked to IBD, with reductions in 'beneficial' bacteria and increases in harmful ones. Certain bacteria, like Faecalibacterium prausnitzii, may serve as markers for disease activity or progression.\n\nDue to the heterogeneity of UC and CD, it is crucial to identify early predictive factors for complications and treatment response. This study aims to identify biological markers of disease course and complications in IBD and to deepen understanding of its pathophysiological mechanisms.",[28,29,30],"Crohn","Ulcerative Colitis (UC)","IBD (Inflammatory Bowel Disease)",[32,33,28,34,35],"Microbiome","Biobank","Ulcerative colitis","IBD","NOT_YET_RECRUITING","2025-09-08",{"date":39,"type":40},"2025-09-15","ACTUAL",{"date":42,"type":22},"2025-09",{"date":44,"type":22},"2040-11",{"name":46,"class":47},"Assistance Publique - Hôpitaux de Paris","OTHER"]